No Data
No Data
Should You Invest In Catalent, Inc. (CTLT) Right Now?
Express News | Lilly Exec Says Concerns Remain About Novo Nordisk-Catalent Acquisition
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Express News | Novo Nordisk CFO Said In Active Dialogue With Antitrust Regulators Over Catalent Deal, Still Expects It To Close Toward End Of Year -Conf Call
Lyophilization Basics for Pharmaceuticals Webinar: History, Scientific Principles, Cycles and Formulations Course (On-Demand) - ResearchAndMarkets.com
Top Gap Ups and Downs on Monday: K, MSTR, TSN and More